Compile Data Set for Download or QSAR
Report error Found 132 Enz. Inhib. hit(s) with all data for entry = 9835
TargetSerine/threonine-protein kinase B-raf(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM16673(Xarelto | BAY439006 | CHEMBL1336 | BAY 43-9006 | 4...)
Affinity DataIC50: 41nMAssay Description:1. Preparation of test compounds: according to the molecular weight of the compounds, an appropriate volume of DMSO was directly added to dissolve th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent
PDB3D3D Structure (crystal)
TargetRAF proto-oncogene serine/threonine-protein kinase(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM16673(Xarelto | BAY439006 | CHEMBL1336 | BAY 43-9006 | 4...)
Affinity DataIC50: 47nMAssay Description:1. Preparation of test compounds: according to the molecular weight of the compounds, an appropriate volume of DMSO was directly added to dissolve th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM492606(US10980809, Example 2)
Affinity DataIC50: 50nMAssay Description:1. Dilution of the compound: a total of 12 concentrations were obtained using a 4-fold gradient dilution from the highest concentration of 10000 nM (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM492608(US10980809, Example 4)
Affinity DataIC50: 50nMAssay Description:1. Dilution of the compound: a total of 12 concentrations were obtained using a 4-fold gradient dilution from the highest concentration of 10000 nM (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM492611(US10980809, Example 7)
Affinity DataIC50: 50nMAssay Description:1. Dilution of the compound: a total of 12 concentrations were obtained using a 4-fold gradient dilution from the highest concentration of 10000 nM (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM492614(US10980809, Example 10)
Affinity DataIC50: 50nMAssay Description:1. Dilution of the compound: a total of 12 concentrations were obtained using a 4-fold gradient dilution from the highest concentration of 10000 nM (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM492615(US10980809, Example 11)
Affinity DataIC50: 50nMAssay Description:1. Dilution of the compound: a total of 12 concentrations were obtained using a 4-fold gradient dilution from the highest concentration of 10000 nM (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM492616(US10980809, Example 12)
Affinity DataIC50: 50nMAssay Description:1. Dilution of the compound: a total of 12 concentrations were obtained using a 4-fold gradient dilution from the highest concentration of 10000 nM (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM492618(US10980809, Example 14)
Affinity DataIC50: 50nMAssay Description:1. Dilution of the compound: a total of 12 concentrations were obtained using a 4-fold gradient dilution from the highest concentration of 10000 nM (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM492619(US10980809, Example 15)
Affinity DataIC50: 50nMAssay Description:1. Dilution of the compound: a total of 12 concentrations were obtained using a 4-fold gradient dilution from the highest concentration of 10000 nM (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM492620(US10980809, Example 16)
Affinity DataIC50: 50nMAssay Description:1. Dilution of the compound: a total of 12 concentrations were obtained using a 4-fold gradient dilution from the highest concentration of 10000 nM (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM492621(US10980809, Example 17)
Affinity DataIC50: 50nMAssay Description:1. Dilution of the compound: a total of 12 concentrations were obtained using a 4-fold gradient dilution from the highest concentration of 10000 nM (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM50524578(CHEMBL4514617 | US10980809, Example 18)
Affinity DataIC50: 50nMAssay Description:1. Dilution of the compound: a total of 12 concentrations were obtained using a 4-fold gradient dilution from the highest concentration of 10000 nM (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM492623(US10980809, Example 19)
Affinity DataIC50: 50nMAssay Description:1. Dilution of the compound: a total of 12 concentrations were obtained using a 4-fold gradient dilution from the highest concentration of 10000 nM (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM50524587(CHEMBL4466426 | US10980809, Example 20)
Affinity DataIC50: 50nMAssay Description:1. Dilution of the compound: a total of 12 concentrations were obtained using a 4-fold gradient dilution from the highest concentration of 10000 nM (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM492625(US10980809, Example 21)
Affinity DataIC50: 50nMAssay Description:1. Dilution of the compound: a total of 12 concentrations were obtained using a 4-fold gradient dilution from the highest concentration of 10000 nM (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM492626(US10980809, Example 22)
Affinity DataIC50: 50nMAssay Description:1. Dilution of the compound: a total of 12 concentrations were obtained using a 4-fold gradient dilution from the highest concentration of 10000 nM (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM50524579(CHEMBL4531859 | US10980809, Example 23)
Affinity DataIC50: 50nMAssay Description:1. Dilution of the compound: a total of 12 concentrations were obtained using a 4-fold gradient dilution from the highest concentration of 10000 nM (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM492628(US10980809, Example 24)
Affinity DataIC50: 50nMAssay Description:1. Dilution of the compound: a total of 12 concentrations were obtained using a 4-fold gradient dilution from the highest concentration of 10000 nM (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM50524585(CHEMBL4470543 | US10980809, Example 25)
Affinity DataIC50: 50nMAssay Description:1. Dilution of the compound: a total of 12 concentrations were obtained using a 4-fold gradient dilution from the highest concentration of 10000 nM (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM492630(US10980809, Example 26)
Affinity DataIC50: 50nMAssay Description:1. Dilution of the compound: a total of 12 concentrations were obtained using a 4-fold gradient dilution from the highest concentration of 10000 nM (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM492631(US10980809, Example 27)
Affinity DataIC50: 50nMAssay Description:1. Dilution of the compound: a total of 12 concentrations were obtained using a 4-fold gradient dilution from the highest concentration of 10000 nM (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM492634(US10980809, Example 30)
Affinity DataIC50: 50nMAssay Description:1. Dilution of the compound: a total of 12 concentrations were obtained using a 4-fold gradient dilution from the highest concentration of 10000 nM (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM492635(US10980809, Example 31)
Affinity DataIC50: 50nMAssay Description:1. Dilution of the compound: a total of 12 concentrations were obtained using a 4-fold gradient dilution from the highest concentration of 10000 nM (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM492636(US10980809, Example 32)
Affinity DataIC50: 50nMAssay Description:1. Dilution of the compound: a total of 12 concentrations were obtained using a 4-fold gradient dilution from the highest concentration of 10000 nM (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM492637(US10980809, Example 33)
Affinity DataIC50: 50nMAssay Description:1. Dilution of the compound: a total of 12 concentrations were obtained using a 4-fold gradient dilution from the highest concentration of 10000 nM (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM492638(US10980809, Example 34)
Affinity DataIC50: 50nMAssay Description:1. Dilution of the compound: a total of 12 concentrations were obtained using a 4-fold gradient dilution from the highest concentration of 10000 nM (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM492639(US10980809, Example 35)
Affinity DataIC50: 50nMAssay Description:1. Dilution of the compound: a total of 12 concentrations were obtained using a 4-fold gradient dilution from the highest concentration of 10000 nM (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM492641(US10980809, Example 37)
Affinity DataIC50: 50nMAssay Description:1. Dilution of the compound: a total of 12 concentrations were obtained using a 4-fold gradient dilution from the highest concentration of 10000 nM (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM492642(US10980809, Example 38)
Affinity DataIC50: 50nMAssay Description:1. Dilution of the compound: a total of 12 concentrations were obtained using a 4-fold gradient dilution from the highest concentration of 10000 nM (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM492643(US10980809, Example 39)
Affinity DataIC50: 50nMAssay Description:1. Dilution of the compound: a total of 12 concentrations were obtained using a 4-fold gradient dilution from the highest concentration of 10000 nM (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM492645(US10980809, Example 41)
Affinity DataIC50: 50nMAssay Description:1. Dilution of the compound: a total of 12 concentrations were obtained using a 4-fold gradient dilution from the highest concentration of 10000 nM (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM492646(US10980809, Example 42)
Affinity DataIC50: 50nMAssay Description:1. Dilution of the compound: a total of 12 concentrations were obtained using a 4-fold gradient dilution from the highest concentration of 10000 nM (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM492647(US10980809, Example 43)
Affinity DataIC50: 50nMAssay Description:1. Dilution of the compound: a total of 12 concentrations were obtained using a 4-fold gradient dilution from the highest concentration of 10000 nM (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM492649(US10980809, Example 45)
Affinity DataIC50: 50nMAssay Description:1. Dilution of the compound: a total of 12 concentrations were obtained using a 4-fold gradient dilution from the highest concentration of 10000 nM (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM492650(US10980809, Example 46)
Affinity DataIC50: 50nMAssay Description:1. Dilution of the compound: a total of 12 concentrations were obtained using a 4-fold gradient dilution from the highest concentration of 10000 nM (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM50524588(CHEMBL4528373 | US10980809, Example 47)
Affinity DataIC50: 50nMAssay Description:1. Dilution of the compound: a total of 12 concentrations were obtained using a 4-fold gradient dilution from the highest concentration of 10000 nM (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM492652(US10980809, Example 48)
Affinity DataIC50: 50nMAssay Description:1. Dilution of the compound: a total of 12 concentrations were obtained using a 4-fold gradient dilution from the highest concentration of 10000 nM (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM492653(US10980809, Example 49)
Affinity DataIC50: 50nMAssay Description:1. Dilution of the compound: a total of 12 concentrations were obtained using a 4-fold gradient dilution from the highest concentration of 10000 nM (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM492654(US10980809, Example 50)
Affinity DataIC50: 50nMAssay Description:1. Dilution of the compound: a total of 12 concentrations were obtained using a 4-fold gradient dilution from the highest concentration of 10000 nM (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM492655(US10980809, Example 51)
Affinity DataIC50: 50nMAssay Description:1. Dilution of the compound: a total of 12 concentrations were obtained using a 4-fold gradient dilution from the highest concentration of 10000 nM (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM492656(US10980809, Example 52)
Affinity DataIC50: 50nMAssay Description:1. Dilution of the compound: a total of 12 concentrations were obtained using a 4-fold gradient dilution from the highest concentration of 10000 nM (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM492657(US10980809, Example 53)
Affinity DataIC50: 50nMAssay Description:1. Dilution of the compound: a total of 12 concentrations were obtained using a 4-fold gradient dilution from the highest concentration of 10000 nM (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM492658(US10980809, Example 54)
Affinity DataIC50: 50nMAssay Description:1. Dilution of the compound: a total of 12 concentrations were obtained using a 4-fold gradient dilution from the highest concentration of 10000 nM (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM492659(US10980809, Example 55)
Affinity DataIC50: 50nMAssay Description:1. Dilution of the compound: a total of 12 concentrations were obtained using a 4-fold gradient dilution from the highest concentration of 10000 nM (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM492660(US10980809, Example 56)
Affinity DataIC50: 50nMAssay Description:1. Dilution of the compound: a total of 12 concentrations were obtained using a 4-fold gradient dilution from the highest concentration of 10000 nM (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM492661(US10980809, Example 57)
Affinity DataIC50: 50nMAssay Description:1. Dilution of the compound: a total of 12 concentrations were obtained using a 4-fold gradient dilution from the highest concentration of 10000 nM (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM492662(US10980809, Example 58)
Affinity DataIC50: 50nMAssay Description:1. Dilution of the compound: a total of 12 concentrations were obtained using a 4-fold gradient dilution from the highest concentration of 10000 nM (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM492663(US10980809, Example 59)
Affinity DataIC50: 50nMAssay Description:1. Dilution of the compound: a total of 12 concentrations were obtained using a 4-fold gradient dilution from the highest concentration of 10000 nM (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Beijing Scitech-Mq Pharmaceuticals

US Patent
LigandPNGBDBM492665(US10980809, Example 61)
Affinity DataIC50: 50nMAssay Description:1. Dilution of the compound: a total of 12 concentrations were obtained using a 4-fold gradient dilution from the highest concentration of 10000 nM (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

Displayed 1 to 50 (of 132 total ) | Next | Last >>
Jump to: